Clinical Trials Logo

Norepinephrine Adverse Reaction clinical trials

View clinical trials related to Norepinephrine Adverse Reaction.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT04339868 Recruiting - Septic Shock Clinical Trials

Terlipressin for Refractory Septic Shock

TERESEP
Start date: April 3, 2020
Phase: Phase 2
Study type: Interventional

Norepinephrine was recommended as the first vasopressor for septic shock resuscitation. For the patient who did not response to high dose norepinephrine, epinephrine was recommended. Vasopressin was also recommended as an alternative vasopressor, in case patient did not response to norepinephrine and or epinephrine. Terlipressin, a selective V1 receptor binding with long half life, was reported that it main action is to increase blood pressure via the different mechanism from norepinephrine and epinephrine. To use terlipressin, combine with norepinephrine and or epinephrine among refractory septic shock, could decrease the usage dose of norepinephrine and epinephrine as well as lower the side effects of too high adrenergic stimuli.